Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALM-1: BLU-5937 (camlipixant) for refractory or unexplained chronic cough
2024-513460-26-00Phase 3Completed
- Sponsor
- BELLUS Health Inc.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in refractory chronic cough (RCC) and chronic idiopathic cough (CIC) comparing Camlipixant (BLU-5937) with Placebo (2 arms). Primary endpoints: 24-hour cough frequency at Week 12, Incidence of adverse events (AEs) and 4 more. Started Sep 2024; status: completed.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on 2024-513460-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513460-26-00.